Eli Lilly CEO Dave Ricks told CNBC on Monday that one-third of new GLP-1 pill patients are taking the drugmaker's Foundayo, as the company tries to catch up to a lead in the space established by rivaтАж [+2382 chars]
No comments yet. Be the first to comment!
┬й 2026 Star News 1. рд╕рд░реНрд╡рд╛рдзрд┐рдХрд╛рд░ рд╕реБрд░рдХреНрд╖рд┐рддред рдЧреЛрдкрдиреАрдпрддрд╛ рдиреАрддрд┐ | рдирд┐рдпрдо рдФрд░ рд╢рд░реНрддреЗрдВ | рдЕрд╕реНрд╡реАрдХрд░рдг
ЁЯЗоЁЯЗ│ рднрд╛рд░рдд рдорд╛рддрд╛ рдХреА рдЬрдп ЁЯЗоЁЯЗ│